In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a decline, ending the day at $439.62 which represents a decrease of $-0.11 or -0.03% from the prior close of $439.73. The stock opened at $438.73 and ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...

Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...